10x genomics CEO Serge Saxonov contributes $1.95M in shares

Serge Saxonov, CEO and director of 10x Genomics, contributed 31,000 shares of the company's stock to an exchange fund on November 10, 2026. The shares, valued at $62.90 each, totaled approximately $1.95 million. As TXG stock has increased by 266% over the past year, the contribution comes amid the stock's current price of $58.19, which is below the exchange fund's valuation.

Post this contribution, Saxonov owns 1,019,249 shares of the company's Class A Common Stock directly, and indirectly holds additional shares through trusts, including 27 shares in the Andromeda Trust, 213,250 shares in the Y/S Descendants' Trust, and 71,644 shares in the Y/S Pot Trust. Investors interested in TXG's valuation and executive holdings can refer to the Pro Research Report on InvestingPro.

Meanwhile, 10x Genomics reported third-quarter 2026 results surpassing Wall Street expectations, posting an adjusted loss per share of $0.15 and revenue of $150.66 million, both beating forecasts. Despite strong performance, the company cautioned on declining margins due to increased shipments of its new Atera spatial biology platform.

Analysts from UBS and Stifel have adjusted their price targets for the company, with UBS setting a Neutral rating at $61 and Stifel raising its Buy rating to $68. The company has also revised its full-year revenue guidance to $625 million to $635 million.